Mingtai Pharmaceutical: Application for market approval of new injection of sodium canotazole has been accepted.

MeiCo Pharmaceuticals announced that the company's application for the market approval of injection of Kenzamycin sodium, a new drug developed independently by the company with global intellectual property rights, has been accepted by the National Medical Products Administration. This drug has been approved in China for the treatment of complicated skin and soft tissue infections. Injection of Kenzamycin sodium is a water-soluble prodrug of Kenzamycin, for which the company has conducted Phase III clinical trials in China successfully meeting the main efficacy endpoints. The indication for application is the treatment of complicated skin and soft tissue infections. The acceptance of the new drug market application will not have a significant impact on the company's recent performance.